See what others miss
Private and underdisclosed segments — university tech transfer royalties, foundation-held streams, partnered-asset royalties at emerging biotechs — are systematically excluded from sell-side mandates. We index them.
Our Firm
A pharmaceutical royalty origination platform.
Capital for Cures helps originate pharmaceutical royalty streams across the long tail of assets the market does not systematically cover. We identify the holders, reconstruct and benchmark the deal terms against four decades of comparables, and introduce the parties who transact. We do not manage capital, hold positions, or place securities. The transactions remain between the holders and the buyers.
Approach
Royalty financing is not the constraint. Origination is.
The royalty funds are well-capitalised and well-staffed. Capital is plentiful, teams are excellent, underwriting standards are mature. The constraint sits earlier in the value chain. No fund's BD organisation, by structural design, has the research bandwidth to systematically scan the full universe of pharmaceutical assets where royalty entitlements actually sit. There are roughly 20,000 drugs and assets in active development globally. More than sixty percent of the royalty-eligible ones sit in the private market — held by university tech transfer offices, research foundations, mid-cap licensors, and emerging biotech with partnered assets. The cash flows have value. The holders frequently want liquidity. The market does not see them.
That work — finding the holders, reconstructing the terms, benchmarking the cash flows, introducing the parties — is what we do. The output is two-sided. Asset owners receive analysis they could not otherwise commission and access to a market they could not otherwise reach. Capital partners — established royalty funds, family offices, institutional allocators — receive originated opportunities in segments they cannot systematically cover with their own BD teams.
Why long-tail origination is hard
Individual sub-$100M positions sit below the practical economics of a major fund's BD process. Origination costs do not scale with transaction size; covering a $30M position requires similar effort to covering a $300M position. Below a fund's internal threshold, the segment goes unoriginated even when individual assets are attractive.
Our intelligence engine closes that coverage gap. We index each position individually, group related ones into thematic portfolios — by therapeutic area, by stage, by structural feature — and benchmark each one against more than four decades of comparable transactions. The capital partner receives a single structured analytical package; holders receive market visibility that would otherwise be unavailable to them at their position size. The transaction itself is between the holder and the buyer.
Our intelligence engine
Coverage at this scale is a data problem. We run domain-trained models on our own infrastructure — no third-party cloud APIs, full data sovereignty — across SEC filings, EDINET (Japan), DART (Korea), CNINFO (China), FDA, EMA, PMDA, clinical trials, patents, court records, university tech transfer disclosures, press, deal documents, credit agreements, and bankruptcy filings. The corpus spans more than four decades of pharmaceutical deal history. Every verified outcome feeds back into training.
The intelligence engine is what makes origination of royalty streams systematic.
The research is the product. The transaction belongs to the parties.
40+ Years of deal history
9 Primary filing jurisdictions
0 Third-party cloud APIs
5+ Languages parsed natively
Why us 01 02 03 04
Built for systematic origination across the long tail.
Four edges, each compounding over time.
Benchmark faster
Every disclosed rate in the therapeutic area, every recent precedent, every comparable structure is mapped into the corpus. Indicative analysis in days, not weeks.
Reduce time to clarity
Comparables are built before the conversation, not during it. The structural baseline is in place before any holder is approached; refinement happens at the margin.
Cover what others can't reach
Sub-$100M positions sit below the practical research economics of major royalty funds' BD teams. Our coverage of that segment is what no fund can replicate internally.
Core team
The people behind the platform.
-
Fifteen years of pharmaceutical business development, including roles at Roche and Abbott, and prior communications experience at Edelman. Has organised more than twenty Capital for Cures events across London, Amsterdam, Paris, and Zurich. Founded Capital for Cures AG to make systematic origination of long-tail royalty streams a service that holders and capital partners can both rely on.
-
Corporate lawyer focused on the life sciences sector. Previously with DZP and Rymarz Zdort Maruta. Co-founded Capital for Cures to bring transactional rigour to royalty origination work.
-
Doctorate in artificial intelligence. Academic affiliations with the University of Cambridge, ETH Zürich, and Queen Mary University of London. Leads the engine work at Capital for Cures: the domain-trained models, the corpus pipeline, and the verified-outcome feedback loop.
Advisory board
Senior practitioners who shape the work.
-
Senior pharmaceutical pricing and market access executive. Leads EVERSANA's global pricing and access practice. Advises Capital for Cures on commercial benchmarks and access dynamics that shape royalty value.
-
Investor with Toledo Capital and InnoSource Ventures, the innovation arm of a multi family office. Advises on capital partner engagement and structuring across the family office and institutional channels.
-
Former Head of M&A and Treasury at MorphoSys, the German biotech acquired by Novartis. Advises on transaction structuring, balance-sheet considerations, and counterparty engagement on the issuer side.
Partnerships
NAVLIN by EVERSANA.
Capital for Cures partners with NAVLIN by EVERSANA for access to commercial pricing and asset data covering more than 5.5 million price points worldwide. The partnership feeds the engine's commercial layer: list prices, net prices, access pathways, and longitudinal price evolution across markets. It complements our own corpus on deal terms, structures, and royalty stacks, and lets us benchmark a position's commercial trajectory against the broader market in the same analytical pass.
Where we sit
Zurich, with a global publication and a European roadshow.
Capital for Cures AG is incorporated and headquartered in Zurich, Switzerland. The team has organised more than twenty Capital for Cures events across London, Amsterdam, Paris, and Zurich, bringing royalty fund analysts, biotech business development, and tech transfer offices into the same room.
We publish a long-form weekly note on royalty-deal mechanics, legal events, and fund positioning — sourced from primary documents — at p05.org. The Weekly Term Sheet covers pharma and biotech deals every week with royalty-stack analysis, advisor league tables, and upstream IP provenance. It is read by royalty fund analysts, biotech BD teams, and tech transfer offices.